Abstract: Objective To observe the efficacy and prognosis of terlipressin treatment in patients with hepatorenal syndrome (HRS), and to investigate its related factors and clinical significance. Methods Data of hospitalized patients with HRS from January 2012 to December 2014 in Changhai hospital before and after terlipressin treatment was collected for analysis of the efficacy and prognosis. Univariate analysis was used to screen related factors according to varied efficacy and prognosis of HRS treated with terlipressin, analysis results of which were verified by logistic regression and receiver operating characteristic (ROC) curve analysis. Results Ninety-six HRS cases treated with terlipressin were enrolled. Among those patients, overall effectiveness was 43.8% with efficiency rate as 32.8% for HRS type I patients and efficiency rate as 65.6% for HRS type II patients. Furthermore, model for end stage liver disease Na (MELD-Na) score, baseline creatinine clearance rate (CCr) and infection incidence were related factors for efficacy of terlipressin treatment. MELD-Na score, total bilirubin (TBil) and efficacy of terlipressin treatment were related factors of prognosis. Conclusion Terlipressin has a satisfactorily curative effect on HRS treatment, efficacy and prognosis of which were associated with basis liver function before terlipressin treatment. Terlipressin should be applied as early as possible. However, efficacy may be poor in patients with higher MELD-Na score.

Key words: Hepatorenal syndrome, Terlipressin, Efficacy, Prognosis, Related factors